Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

BIAF

BioAffinity Technologies Inc

Apr 30 • 04:00PM ET

2.45

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF VTI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.91	Insider Own	52.83%	Shs Outstand	9.39M	Perf Week	-5.41%
Market Cap	28.20M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	5.43M	Perf Month	17.22%
Income	-7.94M	PEG	-	EPS next Q	-	Inst Own	1.36%	Short Float	4.44%	Perf Quarter	53.12%
Sales	2.53M	P/S	11.15	EPS this Y	-	Inst Trans	252.73%	Short Ratio	1.04	Perf Half Y	81.48%
Book/sh	0.52	P/B	4.74	EPS next Y	-	ROA	-77.80%	Short Interest	0.24M	Perf Year	25.64%
Cash/sh	0.25	P/C	10.00	EPS next 5Y	-	ROE	-99.84%	52W Range	0.95 - 3.62	Perf YTD	66.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-19.28%	ROI	-132.87%	52W High	-32.32%	Beta	3.17
Dividend TTM	-	Quick Ratio	1.76	Sales past 5Y	13156.86%	Gross Margin	21.40%	52W Low	156.60%	ATR (14)	0.29
Dividend Ex-Date	-	Current Ratio	1.77	EPS Y/Y TTM	9.30%	Oper. Margin	-314.84%	RSI (14)	50.10	Volatility	10.69% 13.41%
Employees	75	Debt/Eq	0.33	Sales Y/Y TTM	52638.42%	Profit Margin	-313.41%	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.23	EPS Q/Q	-28.48%	Payout	-	Rel Volume	0.00	Prev Close	2.45
Sales Surprise	22.22%	EPS Surprise	-35.00%	Sales Q/Q	94245.95%	Earnings	Apr 01 BMO	Avg Volume	232.40K	Price	2.45
SMA20	-5.59%	SMA50	10.43%	SMA200	43.01%	Trades		Volume	0	Change	0.00%

Apr-24-24 08:00AM	bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth (Business Wire) -5.41%
Apr-09-24 08:00AM	bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening (Business Wire)
Apr-01-24 10:53PM	BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q4 2023 (InvestorPlace)
09:49AM	bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Mar-08-24 01:15PM	Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
12:45PM	Loading…
12:45PM	bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement (Business Wire)
Mar-06-24 10:45AM	WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire) -50.00%
09:46AM	bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement (Business Wire)
Mar-05-24 08:00AM	bioAffinity Technologies Reports Accelerating Sales Growth of CyPath Lung (Business Wire) +27.66%
Feb-21-24 08:00AM	bioAffinity Technologies News Update (Business Wire)
Feb-06-24 08:00AM	Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies Medical and Scientific Advisory Board and Incorporates CyPath Lung into Medical Practice (Business Wire)
Jan-30-24 08:00AM	bioAffinity Technologies In The News (Business Wire)
Jan-23-24 08:00AM	bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer (Business Wire)
Jan-08-24 08:00AM	bioAffinity Technologies In the News (Business Wire)
Jan-05-24 09:00AM	bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
08:00AM	Loading…
Dec-05-23 08:00AM	bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors (Business Wire)
Nov-30-23 08:00AM	CMS Posts Final Payment Determination for bioAffinity Technologies CyPath Lung Effective January 2024 (Business Wire) +22.96%
Nov-28-23 08:00AM	bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post (Business Wire)
Nov-15-23 08:00AM	bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening (Business Wire)
Nov-14-23 04:01PM	bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-06-23 08:00AM	bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales (Business Wire)
Oct-10-23 08:00AM	bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference (Business Wire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire) -31.17%
Sep-19-23 08:00AM	bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services (Business Wire)
Sep-07-23 08:00AM	bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference (Business Wire)
Aug-14-23 05:03PM	bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Jul-12-23 08:00AM	AMA Issues CPT Code for bioAffinity Technologies CyPath® Lung Test for Early-Stage Lung Cancer (Business Wire)
Jun-15-23 08:00AM	bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium (Business Wire)
May-22-23 08:00AM	bioAffinity Technologies Presents Research Findings at CYTO 2023 (Business Wire)
May-15-23 08:00AM	bioAffinity Technologies Reports First Quarter 2023 Financial Results (Business Wire)
08:00AM	Loading…
May-01-23 08:00AM	bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer (Business Wire) +5.13%
Apr-25-23 08:00AM	bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium (Business Wire)
Apr-05-23 08:00AM	bioAffinity Technologies to Ring Nasdaq Closing Bell Today (Business Wire) +7.78%
Mar-31-23 05:52PM	bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire) +5.00%
Mar-28-23 08:00AM	bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer (Business Wire)
Mar-24-23 08:00AM	bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023 (Business Wire)
Feb-13-23 08:00AM	bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications (Business Wire)
Jan-24-23 08:00AM	bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research (Business Wire) +75.47%
Jan-04-23 08:00AM	bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments (Business Wire) +5.77%
Dec-19-22 11:33AM	Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF) (PR Newswire)
Dec-15-22 08:30AM	bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench (Business Wire)
Dec-01-22 08:00AM	bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting (Business Wire)
Nov-14-22 07:30AM	bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-10-22 08:15AM	bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Companys Scientific and Medical Advisory Board (Business Wire) +7.34%
Nov-08-22 08:00AM	bioAffinity Technologies to Report Third Quarter 2022 Financial Results (Business Wire)
Oct-25-22 09:15AM	bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia (Business Wire)
Oct-12-22 08:15AM	bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference (Business Wire)
Sep-28-22 08:15AM	bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M (Business Wire) +37.74%
Sep-14-22 08:15AM	bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONE (Business Wire) +17.39%
Sep-06-22 01:54PM	WallachBeth Capital Announces Closing Of bioAffinity Technologies, Inc. $7.8 Million Initial Public Offering (PR Newswire) -23.55%
11:28AM	bioAffinity Technologies, Inc. Announces Closing of $7.8 Million Initial Public Offering (Business Wire)
Sep-01-22 12:32PM	WallachBeth Capital Announce Pricing Of bioAffinity Technologies IPO At $6.125 Per Unit (PR Newswire)
08:15AM	bioAffinity Technologies Announces Pricing of IPO (Business Wire)

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zannes Maria	President & CEO	Apr 08 '24	Option Exercise	1.16	64,848	75,224	229,506	Apr 24 04:00 PM
Zannes Timothy P	Secretary, EVP, Gen. Counsel	Apr 04 '24	Option Exercise	1.16	64,848	75,224	75,155	Apr 24 04:00 PM
GIRGENTI STEVEN	Director	Apr 03 '24	Option Exercise	1.16	64,848	75,224	1,056,606	Apr 24 04:00 PM
Anderson Robert A.	Director	Feb 26 '24	Option Exercise	1.16	64,848	74,899	121,856	Mar 29 04:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIAF

BioAffinity Technologies Inc

Upgrade your FINVIZ experience